TME Pharma: new data in brain cancer
The biotech announced this morning that another patient with newly-diagnosed glioblastoma receiving NOX-A12, its lead drug candidate, had achieved 18-month survival, bringing overall 18-month survival to 67%.
The 18-month survival rate of patients treated with NOX-A12, in addition to bevacizumab (Avastin) and radiotherapy, is now 13 times higher than the 18-month survival rate of 5% observed in the reference cohort, the company points out.
At the same time, median overall survival continues to improve, and has already exceeded 18 months, compared with a median overall survival of 10.5 months in the reference cohort.
Aram Mangasarian, CEO of TME Pharma, believes that his company has accumulated 'irrefutable' clinical evidence, to such a level that NOX-A12-based therapies now have the potential, in his view, to be considered the best available treatment for glioblastoma patients.
TME Pharma expects to obtain an FDA filing and fast-track access by the end of the first quarter of 2024.
Following these announcements, TME Pharma shares jumped 18% on Friday on the Paris Bourse.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction